Study of mRNA Vaccine Targeting KRAS Mutations for Treating KRAS-Mutated Malignant Tumors
Led by Sichuan University · Updated on 2025-06-24
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of an mRNA vaccine targeting KRAS mutations in malignant tumors. KRAS mutations play a key role in the development and progression of various cancers such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Due to the difficulty in directly targeting KRAS proteins, this study explores mRNA vaccines as a promising new treatment option, either alone or combined with immune checkpoint inhibitors, to improve outcomes for patients with KRAS-mutated cancers.
The study includes two groups one receiving escalating doses of the KRAS-mutated mRNA vaccine alone, and another receiving the vaccine combined with Toripalimab, pemetrexed, and carboplatin as a pre-surgery treatment. Participants in the combination group will undergo surgery after this neo-adjuvant treatment. The trial uses a non-randomized design and aims to assess the vaccines safety and immune response over several months.
Participants will be monitored for adverse events for up to 12 months, and immune responses to the vaccine will be assessed for up to 7 months. Researchers will also measure tumor responses, progression-free survival, overall survival, and surgical feasibility. The study involves regular clinical assessments, laboratory tests, and imaging to evaluate treatment effects and safety throughout the participation period, which may last up to a year.
CONDITIONS
Brief Title
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Presence of primary CNS tumors, active CNS metastatic tumors, or carcinomatous meningitis
Uncontrolled moderate to massive serous cavity effusion
Presence of other classic gene variants
Poorly controlled cardiac symptoms or diseases
Unstable thrombotic events requiring treatment within 6 months
Active or past autoimmune disease
Uncontrolled clinical disorders, psychiatric illnesses, or other significant diseases
History or suspicion of interstitial pneumonia or pulmonary abnormalities
Hypersensitivity to the investigational drug or excipients
Anti-tumor therapy within 4 weeks prior to first dose or unresolved adverse reactions (except alopecia)
Systemic corticosteroids or immunosuppressants within 14 days before first dose
Use of drugs from same class within 6 months before first dose
Prior organ or hematopoietic stem cell transplantation
Active infections including hepatitis B, hepatitis C, HIV, syphilis, tuberculosis
Pregnant or lactating women
Any other factors deemed unsuitable by investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Treatment
Duration - Up to 7 months
Participants receive either a KRAS-mutated mRNA vaccine alone with dose escalation or a combination of KRAS-mutated mRNA vaccine, Toripalimab, pemetrexed, and carboplatin as neo-adjuvant treatment followed by surgery.
Visits vary by cohort and treatment phase
Follow-up
Duration - Up to 12 months
Participants are monitored for adverse events, immunogenicity, and clinical outcomes including response rates and survival for up to 12 months after treatment.
Periodic visits for up to 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase I Study Evaluating Safety and Activity of SSS59 in Patients with Advanced Malignant Tumors
Phase III Study of LM-101 Injection Alone or with Other Drugs for Advanced Malignant Tumors
Evaluating Safety, Dosage, Effects, and Immune Response
Phase III Study of LM-350 to Evaluate Safety, Tolerability, and Preliminary Effectiveness in Adults With Advanced Solid Tumors
Study of mRNA Vaccine Targeting KRAS Mutations for Treating KRAS-Mutated Malignant Tumors
Evaluating 68Ga-FL-031 PET Imaging for Diagnosis and Staging of Small Cell Lung Cancer, Breast Cancer, Nasopharyngeal Carcinoma, and Other Tumors
Study of Gene Features in Malignant Tumors and Their Impact on Patient Outcomes
Phase III Study of LM-299 Injection to Evaluate Safety, Tolerability, and Effectiveness in Adults With Advanced Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Jeffrey S Weber, Matteo S Carlino, Adnan Khattak...